---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-240585"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:37:08.397040+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Annexon reports Phase 2 ANX007 data: 0% vision loss in less advanced GA vs 17% sham

## Summary
- ANX007 monthly-treated patients with less advanced dry AMD lost 0% (0/56) 15+ letters vs 17% (10/59) sham (p=0.0013).
- In overall Phase 2 ARCHER, ANX007 monthly reduced 15+ letter loss to 6% (5/89) vs 21% (19/89) sham (p=0.0021).
- ANX007 showed 61% decrease in EZ loss in patients with <80% EZ intact at baseline (p=0.0575).
- Pivotal Phase 3 ARCHER II data expected in second half 2026.
- ANX007 is a first-in-kind Fab targeting C1q intravitreally; data presented at AAO 2024.

## SEC filing metadata
- accession: 0001193125-24-240585
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000119312524240585/0001193125-24-240585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000119312524240585/d849436d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-240585
- JSON: https://secwatch.observer/filing/0001193125-24-240585.json
- Plain text: https://secwatch.observer/filing/0001193125-24-240585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.